| Literature DB >> 35676560 |
Maria Francesca Rossi1, Antonio Tumminello1, Matteo Marconi2, Maria Rosaria Gualano3, Paolo Emilio Santoro4,5, Walter Malorni6,7, Umberto Moscato1,4,5,8.
Abstract
INTRODUCTION: Gender medicine is a new medical approach aimed at the study of the differences between women and men in terms of prevention, diagnosis, and the outcome of all diseases. Migraines are among these. They represent the most common neurological illness; they are most prevalent in adults between 20 and 50 years of age and are three to four times more frequent in woman than in men. Affecting people in working age, migraines are a problem that strongly impacts the psychophysical health and productivity of workers, regardless of the specific job task they have.Entities:
Keywords: Gender medicine; Headaches; Migraines; Occupational health
Mesh:
Year: 2022 PMID: 35676560 PMCID: PMC9176156 DOI: 10.1007/s10072-022-06178-6
Source DB: PubMed Journal: Neurol Sci ISSN: 1590-1874 Impact factor: 3.830
Main characteristics pertaining to gender differences of screened articles
| Authors | Male/female incidence | Differences in duration, frequency and intensity of attacks | Estrogens hormonal influence | Hormonal, genetic and protein factors |
|---|---|---|---|---|
| Tonini MC, 2018 [ | 13% male–32.9% female | No significant differences for these parameters between women and men | Yes | Polymorphism of the ESR1* receptors |
| Vetvik KG and MacGregor EA, 2017 [ | 2 to 3 times more prevalent in women than in men | Women report longer duration of migraine attacks than men, whilst frequency and intensity are similar | Yes | CGRP**, Galanin, and Neuropeptide Y |
| Gupta S et al., 2011 [ | 2 to 3 times more prevalent in women than in men | These parameters are not considered in the article | Yes | CGRP**, TRPV1***, 5HT**** |
| Krause DN et al., 2021 [ | 3 times more prevalent in women than in men | Frequency and severity of attacks varies during puberty, the menstrual cycle, pregnancy, the postpartum period and menopause | Yes | CGRP** |
| Allais G et al., 2020 [ | 18% male–43% female | Attack frequency is similar in men and women; attack frequency, intensity and duration are age-related and worst in women aged 30 and over | Yes | CGRP** |
| Labastida-Ramírez A et al., 2019 [ | 2 to 3 times more prevalent in women than in men | These parameters are not considered in the article | Yes | Functional interactions between ovarian steroid hormones, CGRP**, and the trigeminovascular system |
| Tsai C-K et al., 2022 [ | 2 to 3 times more prevalent in women than in men | Women have more frequent and intense headaches, and higher risk of chronicization | Yes | CGRP** and the trigeminovascular system |
*estrogen receptor 1; **calcitonin-gene related peptide, ***transient vanilloid receptor 1, ****5-hydroxytryptamine